Trade

with

Agios Pharmaceuticals Inc
(NASDAQ: AGIO)
AdChoices
72.90
+4.65
+6.81%
After Hours :
72.25
-0.65
-0.89%

Open

72.40

Previous Close

68.25

Volume (Avg)

872.46k (542.08k)

Day's Range

70.53-73.99

52Wk Range

15.77-73.99

Market Cap.

2.35B

Dividend Rate ( Yield )

-

Beta

-

Shares Outstanding

34.46M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 25.55M

    • Net Income

    • -39.41M

    • Market Cap.

    • 2.35B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -183.25

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -

    • Forward P/E

    • -

    • Price/Sales

    • 68.03

    • Price/Book Value

    • 11.72

    • Price/Cash flow

    • -34.25

      • EBITDA

      • -37.44M

      • Return on Capital %

      • -28.53

      • Return on Equity %

      • -96.34

      • Return on Assets %

      • -28.53

      • Book Value/Share

      • 5.82

      • Shares Outstanding

      • 34.46M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 34.20

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -180.37

            • 39.38

            • Net Profit Margin

            • -183.25

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 5.49

              • 2.92

              • Quick Ratio

              • 5.43

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.36

              • 2.21

              • Book Value/Share

              • 5.82

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -35.59

                • 238.10

                • P/E Ratio 5-Year High

                • -38.18

                • 634.30

                • P/E Ratio 5-Year Low

                • -8.60

                • 124.82

                • Price/Sales Ratio

                • 65.36

                • 8.94

                • Price/Book Value

                • 11.21

                • 8.12

                • Price/Cash Flow Ratio

                • -34.25

                • 47.85

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -96.34

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -28.53

                    (-)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -96.34

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.16

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -38.88M
                  Operating Margin
                  -152.20
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -34.25
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  92.66%

                  Mutual Fund Ownership

                  39.67%

                  Float

                  24.39%

                  5% / Insider Ownership

                  1.08%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Growth Company Fund

                  •  

                    1,460,280

                  • 3.15

                  • 4.24

                  • Fidelity® Contrafund® Fund

                  •  

                    1,237,644

                  • 0.00

                  • 3.59

                  • Fidelity Advisor® New Insights Fund

                  •  

                    1,210,662

                  • 0.00

                  • 3.51

                  • Lord Abbett Developing Growth Fund

                  •  

                    732,574

                  • 182.64

                  • 2.13

                  • iShares Nasdaq Biotechnology

                  •  

                    460,249

                  • 3.08

                  • 1.40

                  • Eventide Gilead Fund

                  •  

                    395,900

                  • 8.02

                  • 1.15

                  • SPDR® S&P Biotech ETF

                  •  

                    386,519

                  • 0.60

                  • 1.18

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    5,091,646

                  • +39.85%

                  • 14.79

                  • Celgene Corp

                  •  

                    5,014,059

                  • +6.25%

                  • 15.75

                  • Third Rock Ventures, LLC

                  •  

                    3,895,090

                  • -30.00%

                  • 11.31

                  • Flagship Ventures 2007 General Partner LLC

                  •  

                    1,930,369

                  • -50.00%

                  • 5.61

                  • Lord, Abbett & Co LLC

                  •  

                    1,198,440

                  • +175.75%

                  • 3.48

                  • Capital World Investors

                  •  

                    1,132,120

                  • +237.95%

                  • 3.29

                  • Wellington Management Company, LLP

                  •  

                    1,087,432

                  • -1.98%

                  • 3.16

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  -

                  Agios Pharmaceuticals Inc is engaged in the development of medicines to treat the cancer metabolism and inborn errors of metabolism, which are a subset of orphan genetic metabolic diseases.

                  Key People

                  David P. Schenkein

                  CEO/Director/President

                  Kevin P. Starr

                  Chairman of the Board/Director

                  Mr. Glenn Goddard

                  CFO/Chief Accounting Officer/Senior VP, Divisional

                  Mr. Paul J. Clancy

                  Director

                  Perry A. Karsen

                  Director

                  • Agios Pharmaceuticals Inc

                  • 38 Sidney Street

                  • Cambridge, MA 02139

                  • USA.Map

                  • Phone: +1 617 649-8600

                  • Fax: -

                  • agios.com

                  Incorporated

                  2007

                  Employees

                  96

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: